safusidenib

Small molecule

Phase 3underway

Evidence outlook · registrational

Glioma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-12-01.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Glioma
Phase 2 (2)
Glioma
NCT07703436 · Nuvation Bio Inc.
2027-03 – 2032-03 · Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma, Oligodendroglioma, Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted, Astrocytoma IDH Mutant Grade 3, Astrocytoma IDH Mutant Grade 2
What this study did
NCT07832123 · University of Zurich
2027-03 – 2029-09 · Glioma : Oligodendroglioma or Astrocytoma
What this study did
Phase 1 (2)
Glioma
NCT05577416 · Melbourne Health
2022-10-11 – 2025-03-26 · Glioma
What this study did
Other / comorbidity
NCT05814536 · AnHeart Therapeutics Inc.
2023-05-06 – 2024-08-15 · Cholangiocarcinoma With IDH1 Mutation, Solid Tumors With IDH1 Mutation
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Glioma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Safusidenib: this drugPhase 3Small moleculeMutant IDH1not yet gradedNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)not yet gradedNo reviewed efficacy summary in this indication
DordaviproneApprovedSmall moleculeMitochondrial caseinolytic protease P (ClpP), Dopamine D2 receptorWeak signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)
Approved(overall)
Small moleculeMutant IDH1
Reliable signal(overall)
No reviewed efficacy summary in this indication
TemozolomideApprovedSmall moleculeDNA alkylation (O6-guanine)Partial signal
NCT00626990: Overall survival: adjuvant temozolomide vs none, median 82.3 vs 46.9 months, hazard ratio 0.64 (95% CI 0.52 to 0.79), p<0.0001; concurrent temozolomide vs none, 66.9 vs 60.4 months, hazard ratio 0.97 (95% CI 0.73 to 1.28), p=0.76 (CT.gov posted results).
TovorafenibApprovedSmall moleculeKinase InhibitorWeak signalNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
LuvometinibPhase 3Small moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
Abemaciclib (Verzenio)Phase 2Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
OlutasidenibPhase 2Small moleculeMutant IDH1not yet gradedNo reviewed efficacy summary in this indication
CrelosidenibPhase 1Small moleculeMutant IDH1 and IDH2not yet gradedNo reviewed efficacy summary in this indication
VebreltinibPhase 1Small moleculeMETnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow safusidenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Phase 3GliomaRecruiting
Est. primary completion 2028-12-01 · NCT05303519 · CT.gov ↗
What to watch
2029 (2)
March 2029 (1)
Phase 2GliomaNot yet recruiting
Est. primary completion 2029-03 · NCT07832123 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3GliomaNot yet recruiting
Est. primary completion 2029-05 · NCT07712757 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
Phase 2GliomaRecruiting
Est. primary completion 2030-09 · NCT07703436 · CT.gov ↗
What to watch

See the full readout calendar ↗